cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Praxis Precision Medicines I
7 own
12 watching
Current Price
$46.89
$0.3
(0.64%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
207.64M
52-Week High
52-Week High
67.21000
52-Week Low
52-Week Low
0.83000
Average Volume
Average Volume
0.35M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization207.64M
icon52-Week High67.21000
icon52-Week Low0.83000
iconAverage Volume0.35M
iconDividend Yield--
iconP/E Ratio--
What does the Praxis Precision Medicines I do?
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Read More
How much money does Praxis Precision Medicines I make?
News & Events about Praxis Precision Medicines I.
Globe Newswire
10 months ago
BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, ...
Globe Newswire
10 months ago
Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60 mg/day dose to be tested BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating ...
Globe Newswire
1 year ago
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, ...
Globe Newswire
1 year ago
Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in 2H23 Ulixacaltamide demonstrated improvement in modified Activities of Daily Living (mADL) primary ...
Ticker Report
1 year ago
Praxis Precision Medicines, Inc. (NASDAQ:PRAX Get Rating) Equities research analysts at William Blair issued their Q1 2024 earnings estimates for Praxis Precision Medicines in a note issued to investors on Tuesday, February 7th. William Blair analyst M. Minter anticipates that the ...
Frequently Asked Questions
Frequently Asked Questions
What is Praxis Precision Medicines I share price today?
plus_minus_icon
Can Indians buy Praxis Precision Medicines I shares?
plus_minus_icon
How can I buy Praxis Precision Medicines I shares from India?
plus_minus_icon
Can Fractional shares of Praxis Precision Medicines I be purchased?
plus_minus_icon
What are the documents required to start investing in Praxis Precision Medicines I stocks?
plus_minus_icon
What is today’s traded volume of Praxis Precision Medicines I?
plus_minus_icon
What is today’s market capitalisation of Praxis Precision Medicines I?
plus_minus_icon
What is the 52-Week High and Low Range of Praxis Precision Medicines I?
plus_minus_icon
What percentage is Praxis Precision Medicines I down from its 52-Week High?
plus_minus_icon
What percentage is Praxis Precision Medicines I up from its 52-Week Low?
plus_minus_icon
Current Price
$46.89
$0.3
(0.64%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SUTRO BIOPHARMA INC
SUTRO BIOPHARMA INC
$3.63
$-0.14 (-3.71 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$4.51
$-0.07 (-1.53 %)
GENERATION BIO CO
GENERATION BIO CO
$2.80
$0.02 (0.72 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$6.84
$-0.22 (-3.12 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
SUTRO BIOPHARMA INC
SUTRO BIOPHARMA INC
$3.63
$-0.14 (-3.71 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$4.51
$-0.07 (-1.53 %)
GENERATION BIO CO
GENERATION BIO CO
$2.80
$0.02 (0.72 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$6.84
$-0.22 (-3.12 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00